Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Angiotensin II receptor antagonists role in arterial hypertension

Journal of Human Hypertension volume 16, pages S93–S99 (2002)Cite this article

Abstract

Angiotensin II receptor blockers represent a class of effective and well tolerated orally active antihypertensive drugs. Activation of AT1 receptors leads to vasoconstriction, stimulation of the release of catecholamines and antidiuretic hormone and promote growth of vascular and cardiac muscle. AT1 receptor blockers antagonise all those effects. Losartan was the first drug of this class marketed, shortly followed by valsartan, irbesartan, telmisartan, candesartan, eprosartan and others on current investigation. All these drugs have the common properties of blockading the AT1 receptor thereby relaxing vascular smooth muscle, increase salt excretion, decrease cellular hypertrophy and induce antihypertensive effect without modifying heart rate or cardiac output. Most of the AT1 receptor blockers in use controlled blood pressure during the 24 h with a once-daily dose, without evidence of producing tolerance to the antihypertensive effect and being with low incidence of side effects even at long term use. Monotherapy in mild-to-moderate hypertension controls blood pressure in 40 to 50% of these patients; when a low dose of thiazide diuretic is added, 60–70% of patients are controlled. The efficacy is similar to angiotensin-converting enzyme (ACE) inhibitors, diuretics, calcium antagonists and beta-blocking agents. AT1 receptor blockers are specially indicated in patients with hypertension who are being treated with ACE inhibitors and developed side effects such as, cough or angioedema. The final position in the antihypertensive therapy in this special population and other clinical situations, such as left ventricular hypertrophy, heart failure, diabetes mellitus and renal disease, has to be determined in large prospective clinical trials, some of which are now being conducted and seem promising.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Booz GW, Baker KM . Role of type 1 and type 2 angiotensin receptors in angiotensin II-induced cardiomyocyte hypertrophy Hypertension 1996 28: 635–640

    Article  CAS  Google Scholar 

  2. Ford WR, Clanachan AS, Jugdutt BL . Opposite effects of angiotensin AT1 and AT2 receptor antagonist on recovery of mechanical function after ischemia-reperfusion in isolated working rat heart Circulation 1996 94: 3087–3089

    Article  CAS  Google Scholar 

  3. Dzau VJ, Mukoyama M, Pratt RE . Molecular biology of angiotensin receptors: target for drug research J Hypertens 1994 12: S1–S5

    CAS  Google Scholar 

  4. Streeten DH, Anderson GH Jr, Dalakos TH . Angiotensin II blockade: its clinical significance Am J Med 1976 60: 817–824

    Article  CAS  Google Scholar 

  5. Brunner HR, Gavras H, Laragh JH . Specific inhibition of the renin-angiotensin system: a key to understanding blood pressure regulation Prog Cardiovasc Dis 1974 17: 87–98

    Article  CAS  Google Scholar 

  6. Furukawa Y, Kishimoto S, Hishikawa K . Tadeka Chemical Industries Ltd Hypotension imidazole-5 acetic acid derivatives. US Patent 4 355 o40, 20 July 1982.

  7. Wexeler RR et al. Rationale for the chemical development of angiotensin II receptor antagonist Am J Hypertens 1992 5: 209S–220S

    Article  Google Scholar 

  8. Chuiu AT et al. Non peptide angiotensin II receptor antagonists, VIII: characterization of functional antagonism displayed by Dup-753, an orally active antihypertensive agent J Pharmacol Exp Ther 1990 252: 711–718

    Google Scholar 

  9. Gansevoor RT et al. Effects of the angiotensin II antagonists losartan in hypertensivepatients with renal disease J Hypertens 1994 12: S37–S42

    Google Scholar 

  10. de Gasparro M, Bottari S, Levens NR . Characteristics of angiotensin II receptor and their role in cell and organ physiology In: Laragh JH, Brenner BM (eds) Hypertension: Pathophysiology; Diagnosis and Management. Second edition Raven Press Thd: New York 1995 pp 1695–1720

    Google Scholar 

  11. Israelli ZH, Hall WD . Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitors therapy: a review of the literature and pathophysiology Ann Inter Med 1992 117: 234–242

    Article  Google Scholar 

  12. Timmermans PBMW et al. Angiotensin II receptors and functional correlates Am J Hypertens 1992 5: 221S–234S

    Article  CAS  Google Scholar 

  13. Garcha RS, Sever PS, Hugles AD . Action of AT1-receptor antagonist on angiotensin II-induced tone in human isolated subcutaneous resistance arteries Br J Pharmacol 1999 127: 1876–1882

    Article  CAS  Google Scholar 

  14. Morsing P et al. Mechanistic differences of various AT1-receptor blockers in isolated vessels of different origin Hypertension 1999 33: 1406–1413

    Article  CAS  Google Scholar 

  15. Vanderheyden PML et al. Distinction between surmountable and insurmountable selective AT1-receptor antagonists by use of CHO-K1 cells expressing human angiotensin II AT1-receptors Br J Pharmacol 1999 126: 1057–1065

    Article  CAS  Google Scholar 

  16. Chiu AT et al. Nonpeptide angiotensin II receptor antagonists. VII. Cellular and biochemical pharmacology of DUP 753, an orally active antihypertensive agent J Pharmacol Exp Ther 1990 252: 711–718

    CAS  PubMed  Google Scholar 

  17. Corriu C, Bernard S, Schott C, Stoclet JC . Effects of losartan on contractile responses of conductance and resistance arteries from rats J Cardiovasc Pharmacol 1995 26: 688–692

    Article  CAS  Google Scholar 

  18. Noda M et al. Inhibition of rabbit aortic angiotensin II (AII) receptor by CV-11974, a new nonpeptide AII antagonist Biochem Pharmacol 1993 46: 311–318

    Article  CAS  Google Scholar 

  19. Ohlstein E, Brooks D, Feuerstein G, Ruffolo R Jr . Inhibition of sympathetic outflow by the angiotensin II receptor antagonist, eprosartan, but not by losartan, valsartan or irbesartan: relationship to differences in prejunctional angiotensin II receptor blockade Pharmacology 1997 55: 244–251

    Article  CAS  Google Scholar 

  20. Hedner T . Management of hypertension: the advent of new angiotensin II receptor antagonist J Hypertens 1999 17 (Suppl 2): S21–S25

    Google Scholar 

  21. Hein L et al. Behavioural and cardiovascular effects of disrupting the angiotensin II type-2 receptor in mice Nature 1995 377: 744–747

    Article  CAS  Google Scholar 

  22. Ichiki T et al. Effects on blood pressure and exploratory behaviour of mice lack angiotensin II type-2 receptor Nature 1995 377: 748–750

    Article  CAS  Google Scholar 

  23. Tsutsumi Y et al. Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation J Clin Invest 1999 104: 925–935

    Article  CAS  Google Scholar 

  24. Nouet S, Nahmias C . Signal transduction from the angiotensin II AT2 receptor Trends Endocrinol Metab 2000 11: 1–6

    Article  CAS  Google Scholar 

  25. Hollenberg NK, Sever PS . The past, present and future of hypertension management: a potential role for AT1-receptor antagonists JRAA 2000 1: 5–10

    CAS  Google Scholar 

  26. Sasamura H et al. Cloning, characterization and expression of two angiotensin receptor (AT-1) isoforms from the mouse genome Biochem Biophys Res Comun 1992 351: 253–259

    Article  Google Scholar 

  27. de Gasparo M et al. Proposed update of angiotensin receptor nomenclature Hypertension 1995 25: 924–927

    Article  CAS  Google Scholar 

  28. Griendling KK, Murphy TJ, Alexander RW . Molecular biology of the renin-angiotensin system Circulation 1993 87: 1816–1824

    Article  CAS  Google Scholar 

  29. Siragy HM . The role of the AT2 receptor in hypertension Am J Hypertens 2000 13: 62S–67S

    Article  CAS  Google Scholar 

  30. Wong PC et al. Non-peptide angiotensin II receptor antagonists: studies with EXP9270 and DuP 753 Hypertension 1990 15: 823–834

    Article  CAS  Google Scholar 

  31. Markahm A, Goa KL . Valsartan. A review of its pharmacology and therapeutic use in essential hypertension Drug 1997 54: 299–311

    Article  Google Scholar 

  32. Ruilope L . Human pharmacokinetic/pharmaco-dynamic profile of irbesartan: a new potent angiotensin II receptor antagonist J Hypertens Suppl 1997 15: S15–S20

    Article  CAS  Google Scholar 

  33. Criscione L et al. Valsartan: preclinical and clinical profile of an antihypertensive angiotensin II antagonist Cardiovasc Drug Res 1995 13: 230–250

    Article  CAS  Google Scholar 

  34. Weber MA . Comparison of type I angiotensin II receptor blockers and angiotensin-converting enzyme inhibitors in the treatment of hypertension J Hypertens 1997 15: S32–S36

    Article  Google Scholar 

  35. Chan JCN et al. A randomised, double blind, parallel study of the antihypertensive efficacy and safety of losartan potassium compared to felodipine ER in elderlypatients with mild to moderate hypertension J Hum Hypertens 1995 9: 765–771

    CAS  PubMed  Google Scholar 

  36. Mallion JM, Goldberg AI . Global efficacy and tolerability of losartan, and angiotensin II subtype 1-receptor antagonist, in treatment of hypertension Blood Press Suppl 1996 2: 82–86

    CAS  PubMed  Google Scholar 

  37. Soffer BA et al. Effects of losartan on a blackground of hydrochlorothiazide inpatients with hypertension Hypertension 1995 26: 112–117

    Article  CAS  Google Scholar 

  38. Gavras I, Gavras H . Effects of eprosartan versus enalapril in hypertensive patients on the renin angiotensin-aldosterone system and safety parameters; results from a 26 week, double-blind, multicenter study Curr Med Res Opin 1999 15: 15–24

    Article  CAS  Google Scholar 

  39. Zanchetti A . Candesartan cilexitil and enalapril are of equivalent efficacy inpatients with mild to moderate hypertension J Hum Hypertens 1997 11 (Suppl 2): S57–S59

    Google Scholar 

  40. Pouleur HG . Clinical overview of irbesartan: a new angiotensin II receptor antagonist Am J Hypertens 1997 10 (Suppl): 318S–324S

    Article  Google Scholar 

  41. Ponticelli C on behalf of the Eprosartan Study Group. Comparison of the efficacy of eprosartan and enalapril inpatients with severe hypertension Am J Hypertens 1997 10: 128A (Abstract)

    Article  Google Scholar 

  42. Mallion JM et al. Valsartan, a new angiotensin II antagonist; blood pressure reduction in essential hypertension compared with an angiotensin converting enzyme inhibitor, enalapril Blood Press Monit 1997 2: 179–184

    CAS  PubMed  Google Scholar 

  43. Nakashima M, Uematsu T, Kosuge K, Kanamaru M . Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects Eur J Clin Pharmacol 1992 42: 333–335

    Article  CAS  Google Scholar 

  44. Oparil S . Newly emerging pharmacologic differences in angiotensin II receptor blockers Am J Hypertens 2000 13: 18S–24S

    Article  CAS  Google Scholar 

  45. Brunner Hr, Gavras H, Laragh JH, Keenan R . Angiotensin-II blockade in man by sar1-ala8-angiotensin II for understanding and treatment of high blood pressure Lancet 1973 II: 1045–1048

    Article  Google Scholar 

  46. Israili ZH . Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension J Hum Hypertens 2000 14 (Suppl 1): S73–S86

    Article  Google Scholar 

  47. Belt GG et al. Inhibition of angiotensin II pressor response and ex vivo angiotensin II radioligand binding by candesartan cilexetil and losartan in healthy human volunteers J Hum Hypertens 1997 11 (Suppl 2): S45–S47

    Google Scholar 

  48. Gradman AH et al. Assessment of once-daily eprosartan, an angiotensin II antagonist, inpatients with systemic hypertension, Eprosartan Study Group Clin Ther 1999 21: 442–453

    Article  CAS  Google Scholar 

  49. Burnier M, Brunner HR . Angiotensin II receptor antagonists in hypertension Kidney Intern 1998 54 (Suppl 68): S107–S111

    Article  Google Scholar 

  50. Ruddy MC, Kostis JB . Angiotensin II receptor antagonist In: Oparil S, Weber M (eds) Hypertension WB Saunders: Philadelphia 1999 Chapter 71 621–636

    Google Scholar 

  51. Dahlöf B, Pennert K, Hansson L . Reversal of left ventricular hypertrophy in hypertensivepatients: a metaanalysis of 109 treatment studies Am J Hypertens 1992 5: 95–110

    Article  Google Scholar 

  52. Cruickshank JM et al. Reversivility of left ventricular hypertrophy by differing types of antyhipertensive therapy J Hum Hypertens 1992 6: 85–90

    CAS  PubMed  Google Scholar 

  53. Mizuno K et al. Effects of losartan, non-peptide angiotensin II receptor antagonist, on cardiac hypertrophy and the tissue angiotensin II content in spontaneously hypertensive rats Life Sci 1992 51: 367–374

    Article  CAS  Google Scholar 

  54. Bunkerburg B et al. Receptor-mediated effects of angiotensin II on growth of vascular smooth muscle cells from spontaneously hypertensive rats Hypertension 1992 20: 746–754

    Article  Google Scholar 

  55. Thürmann PA et al. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy inpatients with essential hypertension Circulation 1998 98: 2037–2042

    Article  Google Scholar 

  56. Golbert AI, Dunlay MC, Sweet CS . Safety and tolerability of losartan potassium, and angiotensin II receptor antagonist, compared with hydrochrothiazide, atenolol, felodipine AR and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension Am J Cardiol 1995 75: 793–795

    Article  Google Scholar 

  57. Physician Desk Reference 52 edition Medical Economics Data 1999

  58. Chan P et al. Double-blind comparison of losartan, lisinopril and metolazone in elderly hypertensivepatients with previous angiotensin-converting enzyme inhibitor-induced cough J Clin Pharmacol 1997 37: 253–257

    Article  CAS  Google Scholar 

  59. Stettin G et al. One-year persistency and compliance with 5 major classes of antihypertensive therapy (abstract) Clin Pharmacol Ther 1998 63: 197

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical Pharmacology Unit, Center of Biomedical Research, School of Medicine, Universidad Centroccidental Lisandro Alvarado, Barquisimeto, Venezuela

    R Hernández-Hernández, B Sosa-Canache, M J Armas-Hernández, M C Armas-Padilla & R Cammarata

  2. Clinical Pharmacology Unit, Vargas Medical School, Central University of Venezuela, Caracas, Venezuela

    M Velasco

Authors
  1. R Hernández-Hernández
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B Sosa-Canache
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M Velasco
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M J Armas-Hernández
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M C Armas-Padilla
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. R Cammarata
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M J Armas-Hernández.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hernández-Hernández, R., Sosa-Canache, B., Velasco, M. et al. Angiotensin II receptor antagonists role in arterial hypertension. J Hum Hypertens 16 (Suppl 1), S93–S99 (2002). https://doi.org/10.1038/sj.jhh.1001352

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.jhh.1001352

Keywords

This article is cited by

Search

Advanced search

Quick links